← All trials
NCT06565507
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2024
- Primary completion
- Mar 30, 2028
- Completion date
- Dec 30, 2028
- First posted
- Aug 22, 2024
- Last posted
- Nov 1, 2024
- Enrollment
- 544
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cayetano Heredia UniversityLead sponsor
- Cayetano Heredia UniversityOfficial
- Oxfendazole Development GroupCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.